You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Francisco Abadía-Molina -- 3024 2022-04-12 09:22:15 |
2 format correct Catherine Yang Meta information modification 3024 2022-04-12 09:39:59 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Abadía-Molina, F.; Plaza-Diaz, J.; , .; Mackenzie, A. IAPs in Cancer. Encyclopedia. Available online: https://encyclopedia.pub/entry/21619 (accessed on 23 December 2025).
Abadía-Molina F, Plaza-Diaz J,  , Mackenzie A. IAPs in Cancer. Encyclopedia. Available at: https://encyclopedia.pub/entry/21619. Accessed December 23, 2025.
Abadía-Molina, Francisco, Julio Plaza-Diaz,  , Alex Mackenzie. "IAPs in Cancer" Encyclopedia, https://encyclopedia.pub/entry/21619 (accessed December 23, 2025).
Abadía-Molina, F., Plaza-Diaz, J., , ., & Mackenzie, A. (2022, April 12). IAPs in Cancer. In Encyclopedia. https://encyclopedia.pub/entry/21619
Abadía-Molina, Francisco, et al. "IAPs in Cancer." Encyclopedia. Web. 12 April, 2022.
IAPs in Cancer
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers14071671

The Inhibitor of Apoptosis (IAP) family of proteins has emerged as a potential pharmacological target in cancer. Abnormal expression of IAPs can lead to dysregulated cell suicide, promoting the development of different pathologies. In several cancer types, members of this protein family are overexpressed while their natural antagonist (Smac) appears to be downregulated, contributing to the acquisition of resistance to traditional therapy. 

inhibitor of apoptosis proteins apoptosis NF-κB

1. Acute Myeloid Leukemia (AML)

Studies evaluating the role of different IAPs in AM have revealed heterogeneous patient profiles while analyses of IAPs’ expression have failed to provide strong evidence that establishes IAPs as potent individual prognostic markers. In the early 2000s, two studies found a correlation between lower levels of XIAP protein with longer survival [1][2]. However, a third study showed no correlation between the levels of XIAP protein expression and survival was found [3]. In 2007, Hess et al. [4], analyzed pro- and anti-apoptotic gene expression in AML patients, documenting a three-gene, (including BIRC3 (c-IAP2), expression signature associated with poor overall survival (OS) [4]. High levels of ML-IAP/Livin protein have also been correlated with poor OS [5]. A later study, by Pluta et al. [6], evaluated correlations both between XIAP, c-IAP1, c-IAP2 and survivin with each other and with Smac/Diablo in newly diagnosed AML patients. Although XIAP showed strong correlations with c-IAP1 and c-IAP2 and the latter two with each other, no correlation with survivin was observed. Low levels of IAPs were associated with 100% complete remission (CR), while high levels of either one, two or three IAPs significantly reduced the percentage of patients attaining CR. On the other hand, a short OS was influenced by older age (>50), poor risk karyotype, low levels of Smac/DIABLO and high levels of survivin [6]. Along these lines, survivin expression was observed in 98% of the samples and protein and mRNA levels were shown to be higher than any other IAP measured in these patients. Taken together, results from Tamm et al. [1], Carter et al. [3], and Pluta et al. [6], appear to suggest an influence of survivin in OS that is stronger than that of XIAP, although further studies assessing how the presence of individual IAPs affect treatment and CR achievement are clearly required [1][3][6].
Importantly, different authors failed to find similar results when studying younger AML patients. Indeed, despite the classical assumption that childhood cancers are similar to adult ones, evidence against this model is becoming more obvious. Childhood AML was recently defined as a significantly different disease from adult AML at the genetic level [7]. However, genes encoding IAPs were not included in the genomic analysis performed on the infant cohorts as part of the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. Therefore, over time, more and more studies evaluating childhood malignancies as independent diseases have started to appear. Along these lines, some studies have assessed the role of IAPs’ expression on survival and therapeutic response in children. Over the past decade, high levels of XIAP were found to positively correlate with risk groups, worse response to chemotherapy and shorter overall and relapse-free survival [2]. Livin and survivin levels were recently analyzed in two AML subtypes, acute promyelocytic (APL) and non-promyelocytic (non-APL). Survivin-negative patients were observed to exhibit longer survival independently of the AML group. On the other hand, livin negative patients presented longer survivals but only in the APL group. Furthermore, risk of relapse was associated with higher expression of survivin but not livin, although both correlated with higher levels of primary WBC. Taken together, none of them were identified as independent prognostic factors, although associations with other AML poor prognostic factors were evident [8]. While these findings agree with those of Makhlouf et al. [9] and El-Mesallamy et al. [5], they stand in strong contrast to the results presented by Sung et al., Carter et al, Moore et al. or Ibrahim et al. [10][11][12][13].
The overexpression of apollon was correlated with an unfavorable prognosis in pediatric patients, a finding first observed by Sung et al. [13] and later confirmed by Ismail et al. [14]. In both studies, apollon was identified as a promising prognostic factor due to its association with a higher risk of relapse, worse response to chemotherapy and decreased survival. Indeed, cutoff values for the expression of the BIRC6 gene were observed to be potent prognostic metrics for both poor clinical outcomes and worse response to therapy [13][14].
All in all, although the cited studies point towards associations between IAPs and AML, larger cohorts, stratification by relevant factors such as disease subtype, cytogenetic characteristics or age, and unified methodology must be analyzed in future studies. Additionally, data obtained from mRNA levels must be assessed and compared to those of protein in both adult and child populations in order to validate these IAPs as prognostic factors.

2. Chronic Lymphocytic Leukemia (CLL)

Chronic lymphocytic leukemia is the most common leukemia in adults. CLL slowly develops for extended periods of time before showing any symptoms, allowing patients to have normal lives during the early stages. However, in contrast to acute leukemias, which develop much faster, it is harder to cure. CLL is a heterogeneous disease characterized by the accumulation of monoclonal mature CD5+ B cells in lymphoid organs, bone marrow and peripheral blood. The accumulation of CLL cells has classically been suggested to be caused by the inhibition of spontaneous apoptosis, rather than by cell proliferation. In turn, given CLL cells fail to engage apoptotic programs in vivo although not in vitro, as observed by Collin et al. [15], it becomes apparent that the tumor microenvironment might have a role in these differences [15]. In fact, spontaneous apoptosis has been observed to be prohibited in patients with progressive disease compared to those with stable disease, which also correlated with higher expression of cIAP1, cIAP2, XIAP and survivin [16]. Lower Smac/DIABLO protein levels also correlated with progressive disease. Additionally, Grzybowska et al. [16] found the co-expression of survivin and cIAP1to be a negative prognostic factor, since patients presenting it showed shorter OS [16].
Despite the classical definition of CLL as a non-proliferative disease, some studies have paid attention to the proliferative nature of CLL cells found in ‘pseudo-follicles’ formed in lymphoid organs [17]. These cells are known to receive support from accessory cells, such as monocyte-derived nurse-like cells, follicular dendritic cells, BMSCs or T lymphocytes, which provide pro-survival and proliferative signals. Indeed, several pro-survival signaling pathways, including NF-kB, are known to be constitutively activated in CLL [18]. It is believed that such a microenvironment is accountable for resistance to chemotherapeutics. Growing evidence indicates that CLL proliferative cells might be responsible for disease relapse after treatment, so any approach targeting said microenvironment could mean a complete clear out of malignant cells [19]. Purroy et al. [20] sensitized resistant CLL cells to cytotoxic agents by inhibiting survivin expression and inducing apoptosis in an ex vivo model of this microenvironment [20]. Likewise, Zhu et al. [21] achieved sensitization of CLL cells to chemotherapy by modulating the expression of XIAP, among other antiapoptotic proteins, with microRNAs shown to be downregulated in ‘p53 wild-type’ patients from a Chinese cohort [21].

3. Colorectal Carcinoma

Colorectal cancer (CRC), also known as bowel cancer, was the third most diagnosed cancer, and the second most fatal, worldwide in 2018, according to “Las cifras del cancer” report from the SEOM (Sociedad Española de Oncología Médica). Although it is mostly a curable disease, when detected at early stages, when symptoms arise, cancer may already have advanced. Lack of activity, obesity, high-fat diet as well as alcohol and smoking are all risk factors for sporadic CRC. Altered molecular pathways documented in CRC have delineated a large number of potential biomarkers. However, given that current screening methods present specificity, sensitivity and cost limitations, make it has proven difficult to rapidly advance towards personalized and targeted therapies. Additionally, studies aiming for validation of these markers show small sample sizes, have data interpretation limitations and lack standard methodologies causing reproducibility challenges [22]. Despite these barrier, promising advances are being made. EGFR-targeted therapies use the KRAS gene as a predictive marker of response, and anti-VEGF is sometimes used in metastatic disease in combination with chemotherapy [22].
Survivin and cIAP-2 expression were distinctive in elderly groups with CRC compared to younger patients, which suggested age-related differences in CRC. Interestingly, XIAP expression was comparable in normal and cancerous tissues in both young and older patients [23]. The location of both cIAP-1 and cIAP-2 was assessed by Ponnelle et al. [24] who found that, although the proteins were present in both nucleus and cytoplasm, cIAP-1 was most frequently expressed in the nucleus (85%) and cIAP-2 in the cytoplasm (82%) in CRC samples [24]. However, nuclear expression of cIAP-2 was associated with lymphoid infiltrate in the stroma, suggesting a nuclear localization role of both proteins in the pathogenesis of CRC. Similarly, Karasawa et al. [25] observed higher cIAP-2 expression in stage II CRC with lymph node metastasis [25]. These patients also presented early recurrence after fluorouracil-based chemotherapy. Interestingly, lymph node metastases with low levels of cIAP-2 and TUCAN (CARD8) showed a larger percentage of five-year survival in a 2005 study of IAPs’ expression [26].
Correlation between XIAP expression and clinical features or prognosis in CRC have yielded conflicting results with some studies reporting no differential expression between cancerous and surrounding normal tissues, while others observed both higher protein and mRNA expression in the former [23][27]. Guoan et al. [28] showed XIAP staining with immunocytochemistry in the cytoplasm of CRC cells [28]. Also, a significant correlation between higher levels of XIAP and tumor differentiation, venous invasion and Duke’s staging was found. Furthermore, XIAP expression levels varied inversely with different survival indexes, such as PFS or OS, in most studies [27]. Takeuchi et al. [29] described the Akt signaling pathway as an important cascade through which XIAP appeared to be upregulated in C-Met overexpressing CRC cells [29].
Interestingly, livin expression significantly correlated with longer survival in a study by Lee et al. [27] in contrast to what was observed for XIAP, while Takeuchi et al. [29] did not find mRNA or protein overexpression in malignant cells [27][29].
BRUCE/Apollon mRNA was also found to be overexpressed in CRC tissues compared with non-neoplastic samples through cDNA microarrays [30] correlating with unfavorable clinical features. Smac/DIABLO levels have also been evaluated with respect to their prognostic potential in CRC and one study reported its decreased expression as an independent factor for poor prognosis [31].

4. Breast Carcinoma

In 2020, breast cancer was the most commonly diagnosed cancer worldwide, surpassing lung cancer. It is the most common cancer among women and the second most common cause of mortality in this population. However, the establishment of prevention programs, although still challenging, has allowed an increase in early detection and survival of patients [32].
In the last few decades, the discovery of hormonal alterations in breast cancer patients and the application of targeted therapies in populations with specific molecular characteristics have brought therapeutic promise. In terms of IAPs, overexpression in cancerous tissues has been generally observed in comparison to normal tissues. A trend of increasing expression in more advanced diseases is also apparent. Pluta et al., [33] evaluated XIAP, cIAP1, cIAP2 and survivin expression in breast cancer samples at diagnosis. The expression of XIAP and survivin was higher in more advanced cancers. Expression of cIAP-2 was higher in node-positive breast cancer, although cIAP-1 levels did not correlate with clinicopathological features of this malignancy. Higher expression of XIAP was found in most patients compared to control. Its overexpression was also associated with advanced cancer [33]. Yang et al. [34], observed an increase in XIAP expression in higher grades of ductal invasive breast carcinoma and ductal breast carcinoma in situ [34]. Similarly, immunohistochemical assays confirmed its expression in 84% of breast invasive ductal carcinomas with high immunoscores [35]. The distinction between cytoplasmic and nuclear localization has also been made. Zhang et al. [35], reported differential subcellular expressions in breast cancer samples when cytoplasmic XIAP was observed in all the studied cases but nuclear staining in only 43% [35]. Likewise, Xu et al. [36], found higher cytoplasmic expression compared to normal tissues, while nuclear expression showed no difference [36]. Cytoplasmic localization correlated to HER-2 expression status, and mutant-type (P53) status, and was considered to be a prognostic biomarker for basal-like breast cancer. Patients with higher tumor levels of XIAP showed an increased risk of relapse, as observed in database analysis. Zhang et al. [35], reported a significant relationship between nuclear staining of XIAP protein and shorter OS while Pluta et al. [33], observed associations between shorter PFS and XIAP protein expression [33][35]. However, Xu et al. [36], did not find a correlation with DFS or OS [36]. Tumor size, extranodal extension, triple-negative status and poorly differentiated subtypes showed direct associations with XIAP expression in the Middle Eastern population. This study showed a significant relationship with the PI3K pathway, p-AKT, Ki-67 and PARP. XIAP was proven to be an independent prognostic marker [37].
Similar to XIAP expression, survivin expression has been correlated with worse clinicopathological features, such as metastasis, and advanced stage, or size, of the tumor. In addition, ER and progesterone receptor-negative hormonal status was observed in to correlate with survivin level [38]. However, previous studies had not found any correlation with said features [39]. In particular, Adamkov et al. [40], suggested that the disagreement observed between different studies could have an origin in the subcellular localization of survivin [40]. Their experiments led to the determination of survivin expression as a potential prognostic factor for ductal breast carcinoma. A meta-analysis encompassing 15 studies, with a total of 2202 breast cancer patients, confirmed significant associations between positive expression of survivin and worse OS [41].
High expression of livin has been associated with highly-invasive breast cancer cells in opposition to a lower expression in non-invasive cells [42]. Li et al. [42], described the role of livin in cancer cell migration and invasion by means of the activation of Akt signaling and the induction of EMT in vitro and in vivo [42]. Furthermore, as in other malignancies, Smac/DIABLO protein was observed to be lowered in breast cancer samples compared to control [43].
Finally, despite the clear tendency of IAP expression to correlate with poor prognosis, Pluta et al. [33], who observed XIAP, cIAP1, cIAP2 and survivin expression in breast cancer samples at diagnosis, its effect on survival could not be confirmed [33]. IAPs’ patterns of expression in other malignancies, such as bladder, lung or renal cancers, are similar to those presented above and have been further developed by Fulda and Vucic [44] and Che et al. [45]. In glioblastomas, livin is correlated with worse PFS and OS rates. C-IAP1 and cIAP2 have been found to be overexpressed in osteosarcoma, and XIAP’s expression levels were high in esophageal, ovarian and pancreatic cancers [46][47]. Table 1 summarizes the IAPs and cancer.
Table 1. IAPs and cancer. Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; FU, fluorouracil; OS; overall survival.
Cancer Type Observations References
Acute Myeloid Leukemia (AML)
XIAP Lower levels of XIAP correlate with longer survival Tamm et al. [1], Tamm et al. [2]
No correlation between XIAP protein levels and survival Carter et al. [3]
XIAP expression strongly correlates with cIAP1 and cIAP2 but no correlation
with survivin was found. Low IAPs levels point to higher complete remission rate.		 Pluta et al. [6]
Survivin Appear to influence on the OS and it might be stronger than that from XIAP
expression.		 Pluta et al. [6]
cIAP2 High gene expression of cIAP2 is associated with poor OS El-Mesallamy et al. [5]
Livin High level of Livin is correlated with poor OS El-Mesallamy et al. [5]
Childhood AML
XIAP High levels of XIAP positively correlate with risk groups, worse response to
chemotherapy and shorter OS.		 Tamm et al. [2]
Livin Livin negative patients showed longer OS in the acute promyelocytic AML Zareifar et al. [8]
Survivin Survivin negative patients showed longer OS Zareifar et al. [8]
Apollon Overexpression of apollon correlated with unfavorable prognosis. It was
identified as a prognostic factor.		 Ismail et al. [14], Sung et al. [13]
Chronic Lymphocytic Leukemia
XIAP Higher expression of XIAP, cIAP1, cIAP2 and survivin was observed in
patients with progressive disease which also exhibited inhibition of
spontaneous apoptosis.		 Grzybowska-Izydorczyk et al. [16]
Modulation of XIAP expression sensitized CLL cells to chemotherapy in
humans.		 Zhu et al. [21]
Survivin Co-expression of survivin and cIAP1 was related with shorter OS and
identified as a negative prognostic factor.		 Grzybowska-Izydorczyk et al. [16]
Inhibition of survivin sensitized CLL cells to cytotoxic agents and induced
apoptosis in and ex vivo model.		 Purroy et al. [20]
Smac Lower levels of Smac protein correlated with progressive disease. Grzybowska-Izydorczyk et al. [16]
Colorectal Carcinoma (CRC)
Survivin Survivin and cIAP2 expression was characteristic of elderly groups Endo et al. [23]
XIAP XIAP expression was comparable in both normal and cancerous tissue of
old and young patients.		 Endo et al. [23]
XIAP protein and mRNA levels are higher in cancerous tissue compared to
surrounding normal tissue.		 Lee et al. [27], Guoan et al. [28]
cIAPs cIAP1 is most frequently expressed in nucleus while cIAP2 in the cytoplasm.
A role of nuclear localization is suggested to be involved in the pathogenesis
of CRC.		 Ponnelle et al. [24]
Higher cIAP2 levels are observed in stage II CRC either lymphoid metastasis
and higher rate of chemotherapy failure with FU.		 Karasawa et al. [25]
Together with TUCAN, cIAP2 low levels presented positive correlation with
higher five-year survival.		 Krajewska et al. [26]
Livin Livin expression correlated with longer survival Lee et al. [27]
Apollon Apollon was observed overexpressed in CRC tissue and correlated with
unfavorable clinical features.		 Bianchini et al. [30]
Smac Decreased expression of Smac was considered an independent factor for
poor prognosis.		 Endo et al. [31]
Breast Carcinoma
XIAP XIAP and survivin expression was observed to be increased in advanced cancer. Pluta et al. [33]
Increased in XIAP expression was observed in higher grades of ductal
invasive breast carcinoma and ductal breast carcinoma in situ.		 Yang et al. [34]
High percentage of breast invasive ductal carcinoma with high immunoscore
showed high XIAP expression.		 Zhang et al. [35]
Higher cytoplasmic expression is observed compared to normal tissues and
correlated with other molecular abnormalities. It was considered a
prognostic biomarker.		 Xu et al. [36]
High XIAP protein related with shorter OS  
cIAP2 Levels were higher in node positive breast cancer Pluta et al. [33]
cIAP1 cIAP1 levels did not correlate with clinicopathological features Pluta et al. [33]
Survivin Correlated with metastasis, advanced stage and tumor size. Youssef et al. [38]
Positive expression of survivin have significant association with worse OS Song et al. [41]
Livin High expression is observed in high-invasive breast cancer cells compared to
non-invasive cells. Authors described potential role in migration of cancer cells.		 Li et al. [42]
Smac Lower expression was observed compared to healthy tissue Pluta et al. [43]

References

  1. Tamm, I.; Kornblau, S.M.; Segall, H.; Krajewski, S.; Welsh, K.; Kitada, S.; Scudiero, D.A.; Tudor, G.; Qui, Y.H.; Monks, A. Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. Clin. Cancer Res. 2000, 6, 1796–1803.
  2. Tamm, I.; Richter, S.; Oltersdorf, D.; Creutzig, U.; Harbott, J.; Scholz, F.; Karawajew, L.; Ludwig, W.-D.; Wuchter, C. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin. Cancer Res. 2004, 10, 3737–3744.
  3. Carter, B.Z.; Kornblau, S.M.; Tsao, T.; Wang, R.Y.; Schober, W.D.; Milella, M.; Sung, H.G.; Reed, J.C.; Andreeff, M. Caspase-independent cell death in AML: Caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood 2003, 102, 4179–4186.
  4. Hess, C.J.; Berkhof, J.; Denkers, F.; Ossenkoppele, G.J.; Schouten, J.P.; Oudejans, J.J.; Waisfisz, Q.; Schuurhuis, G.J. Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. J. Clin. Oncol. 2007, 25, 1209–1215.
  5. El-Mesallamy, H.O.; Hegab, H.M.; Kamal, A.M. Expression of inhibitor of apoptosis protein (IAP) livin/BIRC7 in acute leukemia in adults: Correlation with prognostic factors and outcome. Leuk. Res. 2011, 35, 1616–1622.
  6. Pluta, A.; Wierzbowska, A.; Cebula-Obrzut, B.; Pluta, P.; Stępka, K.; Szmigielska-Kapłon, A.; Grzybowska-Izydorczyk, O.; Czemerska, M.; Smolewski, P.; Wrzesien-Kus, A. Prognostic value of inhibitor of apoptosis protein family expression in patients with acute myeloid leukemia. Leuk. Lymphoma 2015, 56, 2529–2535.
  7. Bolouri, H.; Farrar, J.E.; Triche, T., Jr.; Ries, R.E.; Lim, E.L.; Alonzo, T.A.; Ma, Y.; Moore, R.; Mungall, A.J.; Marra, M.A.; et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat. Med. 2018, 24, 103–112.
  8. Zareifar, S.; Ghorbani, S.; Monabbati, A.; Bordbar, M.R.; Zekavat, O.R.; Abdolkarimi, B.; Haghpanah, S. Expression of antiapoptotic proteins livin and survivin in pediatric AML patients, as prognostic markers. Pediatr. Hematol. Oncol. 2018, 35, 250–256.
  9. Makhlouf, M.M. Survivin and cyclin E2 genes expression in a cohort of Egyptian acute leukemia patients: Clinical importance and future prospects. Cancer Biomark. 2016, 16, 181–189.
  10. Carter, B.Z.; Qiu, Y.; Huang, X.; Diao, L.; Zhang, N.; Coombes, K.R.; Mak, D.H.; Konopleva, M.; Cortes, J.; Kantarjian, H.M. Survivin is highly expressed in CD34+ 38− leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood J. Am. Soc. Hematol. 2012, 120, 173–180.
  11. Ibrahim, L.; Aladle, D.; Mansour, A.; Hammad, A.; Al Wakeel, A.A.; Abd El-Hameed, S.A. Expression and prognostic significance of livin/BIRC7 in childhood acute lymphoblastic leukemia. Med. Oncol. 2014, 31, 1–8.
  12. Moore, A.S.; Alonzo, T.A.; Gerbing, R.B.; Lange, B.J.; Heerema, N.A.; Franklin, J.; Raimondi, S.C.; Hirsch, B.A.; Gamis, A.S.; Meshinchi, S. BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children′s Oncology Group. Pediatr. Blood Cancer 2014, 61, 647–652.
  13. Sung, K.W.; Choi, J.; Hwang, Y.K.; Lee, S.J.; Kim, H.-J.; Lee, S.H.; Yoo, K.H.; Jung, H.L.; Koo, H.H. Overexpression of Apollon, an antiapoptotic protein, is associated with poor prognosis in childhood de novo acute myeloid leukemia. Clin. Cancer Res. 2007, 13, 5109–5114.
  14. Ismail, E.A.R.; Mahmoud, H.M.; Tawfik, L.M.; Habashy, D.M.; Adly, A.A.M.; El-Sherif, N.H.; Abdelwahab, M.A. BIRC6/Apollon gene expression in childhood acute leukemia: Impact on therapeutic response and prognosis. Eur. J. Haematol. 2012, 88, 118–127.
  15. Collins, R.J.; Verschuer, L.A.; Harmon, B.V.; Prentice, R.L.; Pope, J.H.; Kerr, J.F. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br. J. Haematol. 1989, 71, 343–350.
  16. Grzybowska-Izydorczyk, O.; Cebula, B.; Robak, T.; Smolewski, P. Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur. J. Cancer 2010, 46, 800–810.
  17. Messmer, B.T.; Messmer, D.; Allen, S.L.; Kolitz, J.E.; Kudalkar, P.; Cesar, D.; Murphy, E.J.; Koduru, P.; Ferrarini, M.; Zupo, S. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Investig. 2005, 115, 755–764.
  18. Cuni, S.; Perez-Aciego, P.; Perez-Chacon, G.; Vargas, J.; Sanchez, A.; Martin-Saavedra, F.; Ballester, S.; Garcia-Marco, J.; Jorda, J.; Durantez, A. A sustained activation of PI3K/NF-κ B pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004, 18, 1391–1400.
  19. Herishanu, Y.; Pérez-Galán, P.; Liu, D.; Biancotto, A.; Pittaluga, S.; Vire, B.; Gibellini, F.; Njuguna, N.; Lee, E.; Stennett, L. The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood J. Am. Soc. Hematol. 2011, 117, 563–574.
  20. Purroy, N.; Abrisqueta, P.; Carabia, J.; Carpio, C.; Calpe, E.; Palacio, C.; Castellví, J.; Crespo, M.; Bosch, F. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia 2014, 28, 1993–2004.
  21. Zhu, D.-X.; Zhu, W.; Fang, C.; Fan, L.; Zou, Z.-J.; Wang, Y.-H.; Liu, P.; Hong, M.; Miao, K.-R.; Liu, P. miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 2012, 33, 1294–1301.
  22. Mármol, I.; Sánchez-de-Diego, C.; Pradilla Dieste, A.; Cerrada, E.; Rodriguez Yoldi, M.J. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int. J. Mol. Sci. 2017, 18, 197.
  23. Endo, T.; Abe, S.; Seidlar, H.; Nagaoka, S.; Takemura, T.; Utsuyama, M.; Kitagawa, M.; Hirokawa, K. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol. Immunother. 2004, 53, 770–776.
  24. Ponnelle, T.; Chapusot, C.; Martin, L.; Bonithon-Kopp, C.; Bouvier, A.M.; Plenchette, S.; Rageot, D.; Faivre, J.; Solary, E.; Piard, F. Subcellular expression of c-IAP1 and c-IAP2 in colorectal cancers: Relationships with clinicopathological features and prognosis. Pathol. Res. Pract. 2003, 199, 723–731.
  25. Karasawa, H.; Miura, K.; Fujibuchi, W.; Ishida, K.; Kaneko, N.; Kinouchi, M.; Okabe, M.; Ando, T.; Murata, Y.; Sasaki, H. Down-regulation of cIAP2 enhances 5-FU sensitivity through the apoptotic pathway in human colon cancer cells. Cancer Sci. 2009, 100, 903–913.
  26. Krajewska, M.; Kim, H.; Kim, C.; Kang, H.; Welsh, K.; Matsuzawa, S.-i.; Tsukamoto, M.; Thomas, R.G.; Assa-Munt, N.; Piao, Z. Analysis of apoptosis protein expression in early-stage colorectal cancer suggests opportunities for new prognostic biomarkers. Clin. Cancer Res. 2005, 11, 5451–5461.
  27. Lee, K.-H.; Lee, S.; Lee, H.-M.; Back, S.-C.; Cho, S.-B.; Lee, J.-H. Inhibitors of apoptosis proteins expression and their prognostic significance in colorectal carcinoma. Tic 2011, 9, 10.
  28. Guoan, X.; Xiaomin, W.; Hanning, W.; Kaiyun, C.; Hao, L. Expression of X-linked inhibitor of apoptosis protein in human colorectal cancer and its correlation with prognosis. J. Surg. Oncol. 2009, 100, 708–712.
  29. Takeuchi, H.; Kim, J.; Fujimoto, A.; Umetani, N.; Mori, T.; Bilchik, A.; Turner, R.; Tran, A.; Kuo, C.; Hoon, D.S. X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin. Cancer Res. 2005, 11, 7621–7628.
  30. Bianchini, M.; Levy, E.; Zucchini, C.; Pinski, V.; Macagno, C.; De Sanctis, P.; Valvassori, L.; Carinci, P.; Mordoh, J. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int. J. Oncol. 2006, 29, 83–94.
  31. Endo, K.; Kohnoe, S.; Watanabe, A.; Tashiro, H.; Sakata, H.; Morita, M.; Kakeji, Y.; Maehara, Y. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncol. Rep. 2009, 21, 351–355.
  32. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J. Clin. 2021, 71, 209–249.
  33. Pluta, P.; Jeziorski, A.; Cebula-Obrzut, A.; Wierzbowska, A.; Piekarski, J.; Smolewski, P. Expression of IAP family proteins and its clinical importance in breast cancer patients. Neoplasma 2015, 62, 666–673.
  34. Yang, L.; Cao, Z.; Yan, H.; Wood, W.C. Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res. 2003, 63, 6815–6824.
  35. Zhang, Y.; Zhu, J.; Tang, Y.; Li, F.; Zhou, H.; Peng, B.; Zhou, C.; Fu, R. X-linked inhibitor of apoptosis positive nuclear labeling: A new independent prognostic biomarker of breast invasive ductal carcinoma. Diagn. Pathol. 2011, 6, 1–9.
  36. Xu, Y.-C.; Liu, Q.; Dai, J.-Q.; Yin, Z.-Q.; Tang, L.; Ma, Y.; Lin, X.-L.; Wang, H.-X. Tissue microarray analysis of X-linked inhibitor of apoptosis (XIAP) expression in breast cancer patients. Med. Oncol. 2014, 31, 1–9.
  37. Hussain, A.R.; Siraj, A.K.; Ahmed, M.; Bu, R.; Pratheeshkumar, P.; Alrashed, A.M.; Qadri, Z.; Ajarim, D.; Al-Dayel, F.; Beg, S. XIAP over-expression is an independent poor prognostic marker in Middle Eastern breast cancer and can be targeted to induce efficient apoptosis. BMC Cancer 2017, 17, 640.
  38. Youssef, N.S.; Hewedi, I.H.; Abd Raboh, N.M. Immunohistochemical expression of survivin in breast carcinoma: Relationship with clinicopathological parameters, proliferation and molecular classification. J. Egypt Natl. Canc. Inst. 2008, 20, 348–357.
  39. Tanaka, K.; Iwamoto, S.; Gon, G.; Nohara, T.; Iwamoto, M.; Tanigawa, N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000, 6, 127–134.
  40. Adamkov, M.; Kajo, K.; Vybohova, D.; Krajcovic, J.; Stuller, F.; Rajcani, J. Correlations of survivin expression with clinicomorphological parameters and hormonal receptor status in breast ductal carcinoma. Neoplasma 2012, 59, 30–37.
  41. Song, J.; Su, H.; Zhou, Y.Y.; Guo, L.L. Prognostic value of survivin expression in breast cancer patients: A meta-analysis. Tumour Biol. 2013, 34, 2053–2062.
  42. Li, F.; Yin, X.; Luo, X.; Li, H.-Y.; Su, X.; Wang, X.-Y.; Chen, L.; Zheng, K.; Ren, G.-S. Livin promotes progression of breast cancer through induction of epithelial–mesenchymal transition and activation of AKT signaling. Cell. Signal. 2013, 25, 1413–1422.
  43. Pluta, P.; Cebula-Obrzut, B.; Ehemann, V.; Pluta, A.; Wierzbowska, A.; Piekarski, J.; Bilski, A.; Nejc, D.; Kordek, R.; Robak, T. Correlation of Smac/DIABLO protein expression with the clinico-pathological features of breast cancer patients. Neoplasma 2011, 58, 430–435.
  44. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11, 109–124.
  45. Che, X.; Yang, D.; Zong, H.; Wang, J.; Li, X.; Chen, F.; Chen, X.; Song, X. Nuclear cIAP1 overexpression is a tumor stage-and grade-independent predictor of poor prognosis in human bladder cancer patients. Urol Oncol. 2012, 30, 450–456.
  46. Ma, O.; Cai, W.-W.; Zender, L.; Dayaram, T.; Shen, J.; Herron, A.J.; Lowe, S.W.; Man, T.-K.; Lau, C.C.; Donehower, L.A. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 2009, 69, 2559–2567.
  47. Tchoghandjian, A.; Soubéran, A.; Tabouret, E.; Colin, C.; Denicolaï, E.; Jiguet-Jiglaire, C.; El-Battari, A.; Villard, C.; Baeza-Kallee, N.; Figarella-Branger, D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death Dis. 2016, 7, e2325.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Oncology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Francisco Abadía-Molina , JULIO PLAZA-DIAZ ,
, alex mackenzie
View Times: 741
Revisions: 2 times (View History)
Update Date: 12 Apr 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback